HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis
The DESTINY-Breast06 trial demonstrated survival benefits of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low/ultralow metastatic breast can...